The Italian Observational Study on Severe Osteoporosis (ISSO): 24-month results on incidence of fractures and adherence to treatment

被引:0
|
作者
Idolazzi, L. [1 ]
Maugeri, D. [2 ]
Monti, S. [3 ]
Massarotti, M. [4 ]
Osella, G. [5 ]
Barbagallo, M. [6 ]
Del Fiacco, R. [7 ]
Silvestri, S. [7 ]
机构
[1] Univ Verona, Dept Med, Lilly Rheumatol Unit, I-37100 Verona, Italy
[2] Univ Catania, Cannizzaro Hosp, Geriatr Unit, Catania, Italy
[3] Univ Roma La Sapienza, St Andrea Hosp, Dept Endocrinol, Rome, Italy
[4] Humanitas Res Hosp, Div Rheumatol & Clin Immunol, Rozzano, Italy
[5] Univ San Luigi Gonzaga, Azienda Osped, Med Interna, Orbassano, Italy
[6] Univ Palermo, Dept Internal Med & Geriatr DIBIMIS, Geriatr Unit, I-90133 Palermo, Italy
[7] Lilly Italia, Dept Med, Sesto Fiorentino, Italy
关键词
spine; spinal fractures; observational study; teriparatide; parathyroid hormone; osteoporosis; fractures; osteoporosis therapy; BONE-MINERAL DENSITY; POSTMENOPAUSAL WOMEN; NONVERTEBRAL FRACTURES; VERTEBRAL FRACTURE; RISK; TRIAL; THERAPY;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective To estimate the proportion of patients with very severe osteoporosis (those covered by the reimbursement criteria of the Italian National Health Service) experiencing new vertebral and non-vertebral fragility fractures in the first 24 months of a new anti-osteoporosis treatment. Methods Prospective observational study in men and post-menopausal women (aged > 21 years) initiating anti-osteoporosis treatment for very severe osteoporosis. Eligibility was based on teriparatide (TPD) reimbursement criteria in Italy: incident of vertebral or hip fracture during anti-resorptive treatment (minimum 1 year), or at least three prevalent severe vertebral fractures, or two prevalent severe vertebral fractures and a historical proximal hip fracture. Incidence of new clinical vertebral and non-vertebral fractures was documented by original x-rays and/or radiological reports, and a post-hoc analysis compared data from the TPD monotherapy population versus the total treated group. Results Overall, 767 patients (mean age 72.8 years, 90.7% women) were enrolled in the study, of whom 628, 538, 419 and 424 attended visits at 6, 12, 18 and 24 months, respectively. The most commonly prescribed therapy was TPD (single-agent; 64.5%), then bisphosphonates and other anti-resorptives (33.3%). A combination of different oral treatments was given to 22.5% of the patients. Overall treatment adherence at 24 months was 65.7%. In a post-hoc analysis, the overall incidence of new clinical vertebral and non-vertebral fractures in the total treated population was, respectively, 4.7% and 2.3% in the first 6 months; 1.8% and 1.6% in the 6-12 month period; 2.9% and 1.4% in the 12-18 month period; and 2.2% and 1.0% in the 18-24 month period. Conclusion In patients with very severe osteoporosis, the risk of new vertebral and non-vertebral fractures declined after the first 6 months and remained low throughout the study.
引用
收藏
页码:247 / 253
页数:7
相关论文
共 50 条
  • [21] USE OF A SMALL APERTURE CORNEAL INLAY FOR THE TREATMENT OF PRESBYOPIA: 24-MONTH RESULTS
    Wolfe, Rick
    CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2012, 40 : 56 - 56
  • [22] Adherence to Treatment in Myelofibrosis Patients: Preliminary Results from Italian Romei Observational Study
    Guglielmelli, Paola
    Palandri, Francesca
    Selleri, Carmine
    Cilloni, Daniela
    Mendicino, Francesco
    Mazza, Patrizio
    Pastore, Domenico
    Palumbo, Giuseppe A.
    Siragusa, Sergio
    Pavone, Vincenzo
    Impera, Stefana
    Morelli, Mara
    Passamonti, Francesco
    Breccia, Massimo
    BLOOD, 2019, 134
  • [23] Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women
    N. Freemantle
    S. Satram-Hoang
    E.-T. Tang
    P. Kaur
    D. Macarios
    S. Siddhanti
    J. Borenstein
    D. L. Kendler
    Osteoporosis International, 2012, 23 : 317 - 326
  • [24] Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women
    Freemantle, N.
    Satram-Hoang, S.
    Tang, E. -T.
    Kaur, P.
    Macarios, D.
    Siddhanti, S.
    Borenstein, J.
    Kendler, D. L.
    OSTEOPOROSIS INTERNATIONAL, 2012, 23 (01) : 317 - 326
  • [25] Real-world effectiveness of daily teriparatide in Japanese patients with osteoporosis at high risk for fracture: final results from the 24-month Japan Fracture Observational Study (JFOS)
    Soen, Satoshi
    Fujiwara, Saeko
    Takayanagi, Ryoichi
    Kajimoto, Kenta
    Tsujimoto, Mika
    Kimura, Shuichi
    Sato, Masayo
    Krege, John H.
    Enomoto, Hiroyuki
    CURRENT MEDICAL RESEARCH AND OPINION, 2017, 33 (11) : 2049 - 2056
  • [26] CARIES PROGRESSION IN PRIMARY MOLARS - 24-MONTH RESULTS FROM A MINIMAL TREATMENT PROGRAM
    CRAIG, GG
    POWELL, KR
    COOPER, MH
    COMMUNITY DENTISTRY AND ORAL EPIDEMIOLOGY, 1981, 9 (06) : 260 - 265
  • [27] Odanacatib treatment in postmenopausal women with low bone mineral density: 24-month results
    McClung, M.
    Eisman, J. A.
    Bone, H. G.
    Roux, C.
    Recker, R. R.
    Verbruggen, N.
    Hustad, C. M.
    daSilva, C.
    Kimmel, D.
    Santora, A.
    Ince, A.
    BONE, 2009, 44 (02) : S438 - S438
  • [28] Quality of life during lanadelumab treatment in patients with hereditary angioedema: 24-month results from the enable study
    Saguer, I. Martinez
    Magerl, M.
    Andriotti, T.
    Botha, J.
    Agmon-Levin, N.
    Watt, M.
    Maurer, M.
    ALLERGY, 2023, 78 : 26 - 27
  • [29] Effectiveness and tolerability of electronic cigarette in real-life: a 24-month prospective observational study
    Riccardo Polosa
    Jaymin B. Morjaria
    Pasquale Caponnetto
    Davide Campagna
    Cristina Russo
    Angela Alamo
    MariaDomenica Amaradio
    Alfredo Fisichella
    Internal and Emergency Medicine, 2014, 9 : 537 - 546
  • [30] THE 24-MONTH STUDY OF TREATMENT WITH MONOCLONAL ANTIBODY TO RANKL ON BONE MINERAL DENSITY AND STRUCTURAL DAMAGE IN PATIENTS WITH OSTEOPOROSIS AND RHEUMATOID ARTHRITIS
    Kovalenko, P.
    Dydykina, I.
    Petrova, E.
    Smirnov, A.
    Alexeeva, L.
    Nasonov, E.
    Nasonova, V. A.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 998 - 998